Homepage > Company > Media > Pharma News > 2018 > Acorda Therapeutics' Inbrija Parkinson's disease treatment gets FDA OK

Acorda Therapeutics' Inbrija Parkinson's disease treatment gets FDA OK

Acorda Therapeutics Inc. said Monday the Food and Drug Administration has approved its Inbrija treatment for off episodes in people with Parkinson's disease.

The company said it expects the treatment to be available by prescription in the first quarter of 2019.

"Despite being on treatment, patients may experience OFF periods as Parkinson's progresses, which can be disruptive," said Todd Sherer, chief executive of the Michael J. Fox Foundation.

"We knew we had to help address this unmet need, and this approval is a significant step forward for the community as it provides a new option to manage these gaps in symptom control."

Acorda's stock, which is still inactive in premarket trade, has lost 31% over the past three months, while the S&P 500 SPX, -2.71% has declined 17%.

Dec. 20, 2018

https://www.marketwatch.com/

Read also

Phase 3 trials of treatment combo for hepatitis D expected in 2025

On the heels of positive Phase 2 clinical trial data, Vir Biotechnology is planning for the 2025 launch of a Phase 3 program, dubbed ECLIPSE, to test its treatment combination of tobevibart and elebsi...

Breakthrough Therapy Designation Market Is Booming Worldwide 2024-2032

The Breakthrough Therapy Designation market has witnessed significant growth over the past decade, driven by advancements in technology, shifting consumer preferences, and increasing investments from ...

Veeva Commercial Summit: Increased investment in medical affairs by pharma companies

Veeva’s VP of global medical, Christoph Bug, emphasises the importance of scientific exchange between clinical experts and pharmaceutical companies.

Remix

Remix Therapeutics to Present Preclinical Data Demonstrating Anti-Leukemic Activity of REM-422 in AML at the 66th American Society of Hematology Annual Meeting and Exposition (ASH)